Please read before exploring Peptide Insights
Important: The information on this website is intended for educational and research purposes only.
Peptide Insights provides information about peptides based on published scientific research and clinical literature. This content is designed to help you understand the science, not to guide personal medical decisions.
By continuing, you confirm that you are accessing this information for educational purposes and understand that it does not constitute medical advice.
Mounjaro · Zepbound · Dual GIP/GLP-1 Agonist · LY3298176
The dual-receptor agonist that outperformed every GLP-1 drug in clinical trials
Typical Dose
5–15 mg per week (maintenance)
Route
Subcutaneous
Frequency
Once weekly
Cycle
Ongoing (chronic use)
Tirzepatide is the active ingredient in Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It is the first drug ever approved that targets two hunger-regulating hormones at the same time: GLP-1 and GIP. Think of it as Semaglutide with a second engine. GLP-1 tells your brain you are full and slows your stomach. GIP does something different — it works directly on fat cells and helps your body use insulin more efficiently. Together, these two signals produce weight loss results that no single-receptor drug has matched in clinical trials. In SURMOUNT-1, the largest obesity trial of its kind, participants lost an average of 20.9% of their body weight — roughly 52 pounds — in 72 weeks.
Tirzepatide works on two separate receptor systems simultaneously. The GLP-1 receptor activation is similar to Semaglutide: it tells your brain you are full, slows gastric emptying, and helps your pancreas release insulin when blood sugar rises. The GIP receptor activation is what makes Tirzepatide unique. GIP works directly on fat tissue to reduce fat storage, improves how efficiently your body uses insulin, and appears to amplify the appetite-suppressing effects of GLP-1. The combination produces a synergistic effect — the two signals together are more powerful than either one alone. This is why Tirzepatide consistently outperformed Semaglutide in head-to-head comparisons (SURMOUNT-5 trial: 47% more weight loss vs Semaglutide 2.4mg).
Typical Dose
5–15 mg per week (maintenance)
Dose Range
2.5 mg (starting) to 15 mg (maximum)
Frequency
Once weekly
Route
Subcutaneous injection
Cycle Length
Ongoing (chronic use)
CLINICAL NOTES
Start at 2.5 mg once weekly for 4 weeks. Increase by 2.5 mg every 4 weeks as tolerated: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Most people reach their maintenance dose between weeks 16–20. Slow titration is key to minimizing GI side effects. Requires a prescription.
IMPORTANT DISCLAIMER
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol. Individual responses vary and medical supervision is recommended.
Real experiences from the Peptide Insights community
Have experience with Tirzepatide?
Log in to share your experience and help the community.
No reviews yet for Tirzepatide
Be the first to share your experience.
Get our free 32-page Beginner's Guide — plain-language breakdowns of the top peptides, dosing essentials, and safety basics.
32-page PDF, instant download
Compounds often researched alongside Tirzepatide
The breakthrough GLP-1 agonist for sustainable weight loss
FDA-approved GHRH analog for visceral fat reduction
A fragment of HGH specifically targeting fat metabolism
A growth hormone fragment that targets fat loss without the side effects of HGH